Table 3.
Analysis of anthracycline sub-groups (AC60, FEC75 and FAC50) homogeneity (test Pearson Khi2)
| Patients characteristics | Group FEC75 [n = 23] No (%) | Group FAC50 [n = 20] No (%) | Group AC60 [n = 57] No (%) | p value |
| Age | ||||
| <40 | 8 (34.8%) | 7 (35%) | 14 (24.6%) | 0.53 |
| ≥40 | 15 (65.2%) | 13 (65%) | 43 (75.4%) | |
| Menopausal status | ||||
| No | 20 (90.9%) | 14 (77.8%) | 35 (66%) | 0.075 |
| Yes | 2 (9.1%) | 4 (22.2%) | 18 (34%) | |
| Side | ||||
| Right | 14 (60.9%) | 7 (35%) | 24 (42.1%) | 0.188 |
| Left | 9 (39.1%) | 13 (65%) | 33 (57.9%) | |
| Surgery | ||||
| Mastectomy | 5 (21.7%) | 5 (25%) | 8 (14%) | 0.457 |
| Conservative | 18 (78.3%) | 15 (75%) | 49 (86%) | |
| Histology | ||||
| CCI | 20 (95.2%) | 19 (95%) | 52 (94.5%) | 0.992 |
| CLI | 1 (4.8%) | 1 (5%) | 3 (5.5%) | |
| SBR | ||||
| I | 0 | 1 (5%) | 4 (7.1%) | 0.31 |
| II | 14 (70%) | 10 (50%) | 39 (69.6%) | |
| III | 6 (30%) | 9 (45%) | 13 (23.2%) | |
| Hormonal receptors | ||||
| ER | ||||
| Positive | 18 (81.8%) | 11 (55%) | 42 (76.4%) | 0.106 |
| Negative | 4 (18.2%) | 9 (45%) | 13 (23.6%) | |
| PR | ||||
| Positive | 17 (77.3%) | 7 (35%) | 31 (57.4%) | 0.022 |
| Negative | 5 (22.7%) | 13 (65%) | 23 (42.6%) | |
| Tumour | ||||
| pT1 | 6 (26.1%) | 1 (5%) | 9 (16.1%) | 0.514 |
| pT2 | 10 (43.5%) | 13 (65%) | 32 (57.1%) | |
| pT3 | 7 (30.4%) | 5 (25%) | 13 (23.2%) | |
| pT4 | 0 | 1 (5%) | 2 (3.6%) | |
| pN, axillary | ||||
| pN0 | 6 (26.1%) | 3 (15%) | 9 (15.8%) | 0.807 |
| pN1 | 4 (17.4%) | 4 (20%) | 15 (26.3%) | |
| pN2 | 7 (30.4%) | 5 (25%) | 18 (31.6%%) | |
| pN3 | 6 (26.1%) | 8 (40%) | 15 (26.3%%) | |
FEC75 = 5-fluorouracile 500 mg/m2, epirubicin 75 mg/m2, and cyclophosphamide 500 mg/m2; FAC50 = 5-fluorouracile 500 mg/m2, doxorubicin 50 mg/m2, and cyclophosphamide 500 mg/m2; AC60 = doxorubicin 60 mg and cyclophosphamide 600 mg/m2 ; SBR = Scarf-Bloom-Richardson; DIC = ductal invasive carcinoma; LIC = lobular invasive carcinoma; ER = estrogen receptor; PR = progesterone receptor